Real-World Data / Real-Word Evidence Insights

  1. From Real-World Data To Real-World Impact: Building The Evidence Capability Pharma Actually Needs 3/25/2026

    Learn how companies that treat RWE as an operational capability will be better positioned to design more efficient trials, accelerate therapy adoption, strengthen payer negotiations, and demonstrate value across the healthcare ecosystem.

  2. Making AI Work For Clinical Trial Supply 3/20/2026

    AI is accelerating clinical trials, but supply teams risk falling behind. Explore how smarter planning, data, and experimentation turn AI into real operational impact.

  3. Edge AI Is Reshaping How Clinical Trials Run 3/12/2026

    Edge computing and AI are transforming clinical trials – enabling real time monitoring, decentralized research, and faster, more cost-effective drug development.

  4. How Salk And Sabin Helped Create The Modern Clinical Trial 2/17/2026

    How Jonas Salk and Albert Sabin pioneered double-blind methodology, HeLa cell assays, and IBM data processing – innovations that became the global standard for clinical trials.

  5. Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It 12/9/2025

    Rob Abbott, CEO of ISPOR, breaks down why HEOR timing keeps clashing with ClinOps timelines and offers practical ways to integrate value, evidence, and payer expectations much earlier in development.

  6. Accelerating Clinical Innovation With Open-Source Medical Platforms 12/8/2025

    Openwater CEO Aaron Timm shares how open source can reduce the cost of technology and extend its reach to more hospitals, researchers, and patients.

  7. Penetration Testing In Healthcare: Common Vulnerabilities And Programs To Address Them 10/28/2025

    Explore some of the common pitfalls witnessed in healthcare environments, as well as guidance for implementing a penetration testing program. 

  8. Penetration Testing In Healthcare: HIPAA And GDPR Requirements 10/27/2025

    Learn about penetration testing requirements in the healthcare environment, including clinical research, according to HIPAA and GDPR. 

  9. FDA Vs. MHRA Vs. EMA: Differences In Externally Controlled Trials 10/23/2025

    As the FDA, MHRA, and EMA release draft frameworks on externally controlled trials, sponsors face differing expectations. The U.K. leans pragmatic, the U.S. remains cautious, and Europe’s guidance is still evolving — leaving global trial planners to navigate regulatory gray zones.

  10. RWE Is Growing Up, And Here's Why That Matters 9/29/2025

    Real-world evidence is shifting from the margins to the mainstream of drug development, but data quality, trust, and regulatory clarity remain hurdles. ISPOR is helping set the standards to guide its future.